Evidence That D-Dimer Levels Predict Subsequent Thromboembolic and Cardiovascular Events in Patients With Atrial Fibrillation During Oral Anticoagulant Therapy

Journal of the American College of Cardiology

Volumn 55, Issue 20, 2010, Pages 2225-2231

  Sadanaga, Tsuneaki ^a   Sadanaga, Motoaki ^b   Ogawa, Satoshi ^c  

^a Yatsushiro General Hospital   (Japan)

^b Sadanaga Clinic   (Japan)

^c KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

anticoagulant therapy; atrial fibrillation; cardiovascular events; D dimer; thromboembolic events

Indexed keywords

D DIMER; WARFARIN;

AGED; ARTICLE; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DISEASE ASSOCIATION; FATALITY; FEMALE; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; PERIPHERAL ISCHEMIA; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SUDDEN DEATH; THROMBOEMBOLISM; TRANSIENT ISCHEMIC ATTACK;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ATRIAL FIBRILLATION; CARDIOVASCULAR DISEASES; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; HEART DISEASES; HUMANS; INTERNATIONAL NORMALIZED RATIO; LOGISTIC MODELS; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RISK FACTORS; ROC CURVE; THROMBOEMBOLISM;

EID: 77951912589     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2009.12.049     Document Type: Article

References (11)

1. Hart R.G., Pearce L.A., and Aguilar M.I. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 146 (2007) 857-867
2. Stroke Prevention in Atrial Fibrillation Investigators. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial. Lancet 348 (1996) 633-638
3. Go A.S., Hylek E.M., Chang Y., et al. Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice?. JAMA 290 (2003) 2685-2692
4. Lip G.Y.H., Lowe G.D.O., Rumley A., and Dunn F.G. Increased markers of thrombogenesis in chronic atrial fibrillation: effects of warfarin treatment. Br Heart J 73 (1995) 527-533
5. Mahe′ I., Drouet L., Chassany O., et al. D-dimer: a characteristic of the coagulation state of each patient with chronic atrial fibrillation. Thrombosis Research 107 (2002) 1-6
6. Nozawa T., Inoue H., Hirai T., et al. D-dimer level influences thromboembolic events in patients with atrial fibrillation. Int J Cardiol 109 (2006) 59-65
7. Vene N., Mavri A., Kosmelj K., and Stegnar M. High D-dimer levels predict cardiovascular events in patients with chronic atrial fibrillation during oral anticoagulant therapy. Thromb Haemost 90 (2003) 1163-1172
8. Stein P.D., Hull R.D., Patel K.C., et al. D-dimer for the exclusion of acute venous thrombosis and pulmonary embolism: a systematic review. Ann Intern Med 140 (2004) 589-602
9. Sodeck G., Domanovits H., Schillinger M., et al. D-dimer in ruling out acute aortic dissection: a systematic review and prospective cohort study. Eur Heart J 28 (2007) 3067-3075
10. Yamaguchi T., and Japanese Nonvalvular Atrial Fibrillation-Embolism Secondary Prevention Cooperative Study Group. Optimal intensity of warfarin therapy for secondary prevention of stroke in patients with nonvalvular atrial fibrillation: a multicenter, prospective, randomized trial. Stroke 31 (2000) 817-821
11. Ogawa S., Aizawa F., Atarashi H., et al. Guidelines for pharmacotherapy of atrial fibrillation (JCS 2008). (in Japanese). Circ J 72 Suppl (2008) 1581-1638